Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment

Hepatology

Volumn 25, Issue 2, 1997, Pages 291-294

  Swain, Mark G ^a   Maric, Mirjana ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; LY 293284; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ACUTE HEPATITIS; ANIMAL MODEL; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; DRUG EFFECT; FATIGUE; LIVER DISEASE; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; SWIMMING; TOXIC HEPATITIS;

EID: 0031032710     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250206     Document Type: Article

References (31)

1. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, et al. The demography of primary biliary cirrhosis in Ontario, Canada. HEPATOLOGY 1990;12:98-105.
2. Hart BL. Biological basis of the behaviour of sick animals. Neurosci Biobehav Rev 1988;12:123-127.
3. Kent S, Bluthe R-M, Kelley KW, Dantzer R. Sickness behaviour as a new target for drug development. TIPS 1992;13:24-28.
4. Jones EA. Fatigue associated with chronic liver disease: a riddle wrapped inside a mystery inside an enigma. HEPATOLOGY 1995;22:1606-1608.
5. Swain MG, Patchev V, Vergalla J, Chrousos GP, Jones EA. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. J Clin Invest 1993;91:1903-1908.
6. Swain MG, Maric M. Defective corticotropin-releasing hormone mediated neuroendocrine and behavioural responses in cholestatic rats: implications for cholestatic liver disease-related sickness behaviours. HEPATOLOGY 1995;22:1560-1564.
7. Sternberg EM, Glowa JR, Smith MA, Cologero AE, Listwak SJ, Aksentijevich S, Chrousos GP, et al. Corticotropin releasing hormone related behavioural and neuroendocrine responses to stress in Lewis and Fischer rats. Brain Res 1992;570:54-60.
8. Bearn J, Wessely S. Neurobiological aspects of the chronic fatigue syndrome. Eur J Clin Invest 1994;24:79-90.
9. Bakheit AMO, Behan PO, Dinan TG, Gray CE, O'Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Br Med J 1992;304:1010-1012.
10. Calogero AE, Bagdy G, Szemeredi K, Tartaglia ME, Gold PW, Chrousos GP. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 1990;126: 1888-1894.
11. Weiss JM, Simson PG, Hoffman LJ, Ambrose MJ, Cooper S, Webster A. Infusion of adrenergic receptor agonists and antagonists into the locus coeruleus and ventricular system of the brain effects on swim-motivated and spontaneous motor activity. Neuropharmacology 1986;25:367-384.
12. Cameron GR, Oakley CL. Ligation of the common bile duct. J Pathol Bacteriol 1932;35:769-798.
13. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. Carbon Tetrachloride. New York: Appleton-Century-Crofts, 1979:198-217.
14. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;226:730-732.
15. 1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther 1994;270:1270-1281.
16. 1A) messenger ribonucleic acid abundance and serotonin levels parallel the activity of the hypothalamopituitary-adrenal axis in rat. J Neurochem 1992;59:1062-1070.
17. 2 release. Am J Physiol 1995;268:G404-G409.
18. 1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol 1987;134:265-274.
19. David A. Postviral fatigue syndrome and psychiatry. Br Med Bull 1991; 47:966-988.
20. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue and quality of life in primary biliary cirrhosis [Abstract]. HEPATOLOGY 22;1995:108A.
21. Roth BL. Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psych 1994;6:67-78.
22. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharm Rev 1994;46:158-201.
23. Curzon G. 5-Hydroxytryptamine and corticosterone in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:305-310.
24. Farrell RJ, Khan I, Maloney M, Farrell J, McDonald GSA, Keeling PWN. Correlation between symptoms, aminotransferases and liver histology in IVDA hepatitis C patients [Abstract]. Gastroenterology 1995;108:A1064.
25. Kirby LG, Allen AR, Lucki I. Regional differences in the effects of forced swimming on extracellular levels of 5-hydroxytryptamine and 5-hydroxyindoleactic acid. Brain Res 1995;682:189-196.
26. Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis [Letter]. N Engl J Med 1994;330:1540.
27. Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res 1992;597:331-338.
28. Jones EA, Bergasa NV. Hypothesis - the pruritus of cholestasis: from bile acids to opiate antagonists. HEPATOLOGY 1990;11:884-887.
29. Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993;74:3006-3012.
30. Bailey SP, Davis JM, Ahlborn EN. Effect of increased brain serotonergic activity on endurance performance in the rat. Acta Physiol Scand 1992; 145:75-76.
31. Wilson WM, Maughn RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992;77:921-924.